外体
微泡
生物素化
生物标志物
纳米粒子跟踪分析
抗体
化学
表面等离子共振
癌症研究
分子生物学
纳米颗粒
生物
医学
纳米技术
材料科学
免疫学
生物化学
基因
小RNA
作者
Linlin Liu,Abhimanyu Thakur,Wing Kar Li,Guangyu Qiu,Tian Yang,Bing He,Youngjin Lee,Chi‐Man Lawrence Wu
标识
DOI:10.1016/j.cej.2022.137383
摘要
Glioblastoma (GBM) is an incurable brain tumor in which hypoxic GBM cells (GMs) increase the production and release of exosomes, which are 30–200 nm vesicles crossing the blood–brain-barrier, enabling exosomal biomarkers to be promising targets for the tracking of GBM malignancy. Here, a localized surface plasmon resonance (LSPR) sensor chip was developed to detect an infinitesimal amount of exosomal biomarkers. Self-assembly silver nanoparticles decorated on gold nano-islands ([email protected]) sensor chip was used to provide site-specific bio-conjunction of biotinylated antibodies for detection of exosomal surface biomarkers. The biotinylated antibody functionalized (BAF) [email protected] LSPR biosensor sensitively detected cluster of differentiation 63, an exosome marker, and monocarboxylate transporter 4 (MCT4), a GBM progression biomarker, in malignant GMs-derived exosomes in the dynamic range of 3.8 × 10−4 to 50 μg/ml with limit of detection (LOD) of 0.38 ng/ml and 1.4 × 10−3 to 500 μg/ml with LOD of 1.4 ng/ml, respectively. Furthermore, it detected the enhanced level of MCT4 in malignant hypoxic GMs-derived exosomes as well as increased MCT4 in the blood serum-derived exosomes of GBM mice in the dynamic range of 4 × 10−4 to 50 μg/ml with LOD of 0.4 ng/ml. Finally, it could quantify MCT4 in the isolated GMs-derived exosomes from the blood of GBM mice by epidermal growth factor receptor variant III-based immunocapture, suggesting its utility for minimally-invasive monitoring of GBM progression as liquid biopsy. With excellent attributes of high sensitivity and selectivity in label-free sensing for exosomal biomarkers, the BAF [email protected] LSPR biosensor has great potential for early detection of GBM formation and progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI